(1) National Program of Cancer Registries [ https://www.cdc.gov/cancer/npcr/index.htm ] and Surveillance, Epidemiology, and End Results [ http://seer.cancer.gov ] SEER*Stat Database (2001-2019) - United States Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute. Based on the 2021 submission.

(3) Due to data availability issues, the time period used in the calculation of the joinpoint regression model may differ [ statecancerprofiles.cancer.gov/historicaltrend/differences.html ] for selected counties. 

(5) Data on Hispanic and non-Hispanic mortality may be unreliable for the time period used in the generation of the recent trend (1990 - 2020) for this state and the user is cautioned against drawing conclusions from such data. This was based on the NCHS Policy. 

6 Source: National Program of Cancer Registries SEER*Stat Database (2001-2019) - United States Department of Health and Human Services, Centers for Disease Control and Prevention (based on the 2021 submission).  [ https://www.cdc.gov/cancer/npcr/index.htm ]

7 Source: SEER November 2021 submission.

8 Source: Incidence data provided by the SEER Program. ( http://seer.cancer.gov ) AAPCs are calculated by the Joinpoint Regression Program ( https://surveillance.cancer.gov/joinpoint/ ) and are based on APCs. Data are age-adjusted to the 2000 US standard population ( http://www.seer.cancer.gov/stdpopulations/single_age.html ) (19 age groups: <1, 1-4, 5-9, ... , 80-84,85+). Rates are for invasive cancer only (except for bladder cancer which is invasive and in situ) or unless otherwise specified. Population counts for denominators are based on Census populations as modifed by NCI. The US Population Data ( http://seer.cancer.gov/popdata/ ) File is used with SEER November 2021 data. 

(9) Hispanic mortality data for the United States has been excluded for the following states: Louisiana, New Hampshire, and Oklahoma. The data on Hispanic and non-Hispanic mortality for these states may be unreliable for the time period used in the generation of the recent trend (1990 - 2020) and has been excluded from the calculation of the United States recent trend. This was based on the NCHS Policy. 

* Data has been suppressed to ensure confidentiality and stability of rate estimates.  Counts are suppressed if fewer than 16 records were reported in a specific area-sex-race category. If an average count of 3 is shown, the total number of cases for the time period is 16 or more which exceeds suppression threshold (but is rounded to 3).

[P4 note] Data for Puerto Rico is only available for All Races (includes Hispanics) For more information see data not available [ https://statecancerprofiles.cancer.gov/datanotavailable.html ].

[rate note1] Incidence rates (cases per 100,000 population per year) are age-adjusted to the 2000 US standard population [http://www.seer.cancer.gov/stdpopulations/stdpop.19ages.html] (19 age groups: <1, 1-4, 5-9, ... , 80-84, 85+). Rates are for invasive cancer only (except for bladder cancer which is invasive and in situ) or unless otherwise specified. Rates calculated using SEER*Stat. Population counts for denominators are based on Census populations as modified [https://seer.cancer.gov/popdata/] by NCI. The US Population Data File [https://seer.cancer.gov/popdata/] is used for SEER and NPCR incidence rates.

[rate note2]Death data provided by the National Vital Statistics System public use data file.  Death rates calculated by the National Cancer Institute using SEER*Stat.  Death rates are age-adjusted  to the 2000 US standard population [http://www.seer.cancer.gov/stdpopulations/stdpop.19ages.html] (19 age groups: <1, 1-4, 5-9, ... , 80-84, 85+).  The Healthy People 2030 goals are based on rates adjusted using different methods but the differences should be minimal.  Population counts for denominators are based on Census populations as modified by NCI. 

[rank note5]Results presented with the CI*Rank statistics help show the usefulness of ranks. For example, ranks for relatively rare diseases or less populated areas may be essentially meaningless because of their large variability, but ranks for more common diseases in densely populated regions can be very useful. More information about methodology can be found on the CI*Rank website.

^ All Stages refers to any stage in the Surveillance, Epidemiology, and End Results (SEER) summary stage [ https://seer.cancer.gov/tools/ssm/ ].

Created by statecancerprofiles.cancer.gov on 05/26/2023 10:17 am.

Data for the United States does not include data from Nevada or Puerto Rico

Please note that the data comes from different sources. Due to different years ( /historicaltrend/differences.html ) of data availability, most of the trends are AAPCs based on APCs but some are APCs calculated in SEER*Stat. ( https://seer.cancer.gov/seerstat/ ) Please refer to the source for each graph for additional information. 

Rates and trends are computed using different standards for malignancy. For more information see malignant.html.

State Cancer Registries may provide more current or more local data.

The US Population Data File [https://seer.cancer.gov/popdata/] is used with mortality data.